These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 15539971

  • 1. Pharmacologic advances in long-term heart failure management.
    Pfeffer MA.
    Am Heart Hosp J; 2004; 2(4 Suppl 1):15-20. PubMed ID: 15539971
    [Abstract] [Full Text] [Related]

  • 2. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 3. Heart failure: recent advances in prevention and treatment.
    Fonarow GC.
    Rev Cardiovasc Med; 2000 Feb; 1(1):25-33, 54. PubMed ID: 12457149
    [Abstract] [Full Text] [Related]

  • 4. An approach to heart failure and diabetes mellitus.
    Fonarow GC.
    Am J Cardiol; 2005 Aug 22; 96(4A):47E-52E. PubMed ID: 16098844
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 22; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 6. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR, Krum H.
    Curr Opin Cardiol; 2006 Jul 22; 21(4):393-9. PubMed ID: 16755210
    [Abstract] [Full Text] [Related]

  • 7. [Triple/quadruple therapy in heart failure: integrating scientific evidence with clinical reasoning].
    Sinagra G, Sabbadini G, Zecchin M, Di Lenarda A.
    G Ital Cardiol (Rome); 2007 Sep 22; 8(9):559-67. PubMed ID: 17972425
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy with ACE inhibitors and angiotensin-receptor blockers in heart failure.
    Scow DT, Smith EG, Shaughnessy AF.
    Am Fam Physician; 2003 Nov 01; 68(9):1795-8. PubMed ID: 14620599
    [Abstract] [Full Text] [Related]

  • 9. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG.
    Eur Heart J; 2005 Dec 01; 26(24):2706-13. PubMed ID: 16183692
    [Abstract] [Full Text] [Related]

  • 10. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Dec 01; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 11. Neurohormonal antagonism in heart failure: what is the optimal strategy?
    Sackner-Bernstein JD, Hart D.
    Mt Sinai J Med; 2004 Mar 01; 71(2):115-26. PubMed ID: 15029403
    [Abstract] [Full Text] [Related]

  • 12. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S.
    Kyobu Geka; 2007 Jun 01; 60(6):484-7. PubMed ID: 17564066
    [Abstract] [Full Text] [Related]

  • 13. [ACE inhibitors, beta blockers, AT-1 antagonists in heart failure. Right dosage and combination].
    Fliri M.
    MMW Fortschr Med; 2002 Nov 28; 144(48):38-43. PubMed ID: 12532542
    [Abstract] [Full Text] [Related]

  • 14. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA.
    Am J Cardiol; 2006 May 22; 97(10A):26F-33F. PubMed ID: 16698332
    [Abstract] [Full Text] [Related]

  • 15. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 16. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL, Baker WL, White CM.
    Curr Med Res Opin; 2007 Jun 16; 23(6):1239-44. PubMed ID: 17559720
    [Abstract] [Full Text] [Related]

  • 17. The HF epidemic: the need for new treatment strategies.
    Carson PE.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 16; 1(2 Suppl):S32-4. PubMed ID: 17199218
    [Abstract] [Full Text] [Related]

  • 18. Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review.
    Fonarow GC, Gheorghiade M, Abraham WT.
    Am J Cardiol; 2004 Nov 01; 94(9):1155-60. PubMed ID: 15518610
    [Abstract] [Full Text] [Related]

  • 19. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R, Borelli G, Coceani M, Zingaro S, Barison A, Morelli I, Rondinini L.
    J Clin Pharm Ther; 2008 Aug 01; 33(4):349-56. PubMed ID: 18613852
    [Abstract] [Full Text] [Related]

  • 20. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
    Vonder Muhll I, Liu P, Webb G.
    Int J Cardiol; 2004 Dec 01; 97 Suppl 1():25-33. PubMed ID: 15590076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.